What are the goals of this research study?
The goal of this research study is to test an investigational medication in adolescents ages 12-17 with 22q11.2 deletion syndrome (22q11.2DS) and Attention Deficit Hyperactivity Disorder, Anxiety Disorder, and/or Autism Spectrum Disorder. The investigational study drug being tested is called Fasoracetam or NFC-1 and has not been approved. This study is sponsored by Medgenics, Inc.

Who can be a part of this research study?
Individuals aged 12 to 17 years old with 22q11.2DS and Attention Deficit Hyperactivity Disorder and/or Anxiety Disorder and/or Autism Spectrum Disorder may be eligible to participate in this study.

What will participants be asked to do?
All participants will be asked to take the study drug for approximately 5 weeks. Some participants will then be given the study drug or a placebo (a look-alike capsule that has no active drug in it) up to an additional 7 weeks. This study involves up to 14 study visits to CHOP over a period of up to 17 weeks for ongoing assessment. The study also involves two telephone calls with study staff. Study medication, study-related medical care and compensation for time and travel may also be provided. Participants will receive summary results of their academic strengths and weakness and any psychiatric findings.

What are the benefits of taking part in this research study?
The results of this study may provide information that could help improve available treatment in the future for individuals with 22q11.2DS.

I want to help! Who do I call?
For more information, please contact the 22q and You Center by phone at (215)-590-2920 or by email at genetics@email.chop.edu.